Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation

Transplantation

Volumn 76, Issue 5, 2003, Pages 877-881

  Pavletic, Steven Z ^a,d   Gregory Bociek, R ^a   Foran, James M ^a   Rubocki, Ronald J ^a   Kuszynski, Charles A ^a   Wisecarver, James L ^a   Hatcher, Lori ^a   Lucas, David M ^c   Byrd, John C ^c   Grever, Michael R ^c   Joshi, Shantaram S ^b   Hardiman, Penny ^a   Smith, Lynette M ^b   McGuire, Timothy R ^b   Bierman, Philip J ^a   Vose, Julie M ^a   Armitage, James O ^a   Talmadge, James E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; LEUKOCYTE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN;

ADULT; AGED; ARTICLE; CHIMERA; CLINICAL ARTICLE; DONOR; DRUG EFFECT; DRUG SAFETY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKOCYTE; LYMPHOCYTE DEPLETION; MALE; MONOCYTE; MONONUCLEAR CELL; NEUTROPHIL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; PENTOSTATIN; PILOT PROJECTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0141478854     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000084869.08639.A0     Document Type: Article

References (10)

1. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
2. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 1995; 13: 974-982.
3. Kurzock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999; 17: 3117-3121.
4. Bayer RL, Feldman EJ, Coleman M, et al. Pentostatin based non-myeloablative conditioning regimen in patients with high-risk hematologic malignancy [abstract]. Blood 2000; 96: 327a.
5. Liu D, Seiter K, Kancherla R, et al. Mitoxantrone, ARAC, and pentostatin: A novel non-myeloablative conditioning regimen (MAP regimen) for hematological malignancies [abstract]. Biol Blood Marrow Transplant 2002; 8: 80.
6. Chan GW, Gorgun G, Miller KB, et al. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 170-176.
7. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
8. Grever MR, Slaw MFE, Jacob WF, et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981; 57: 406-417.
9. Ageitos A, Ino K, Ozerol I, et al. Restoration of T and NK cell function in mobilized stem cell products by monocyte depletion. Bone Marrow Transplant 1997; 20: 172-173.
10. Rubocki RJ, Parsa JR, Hershfield MS, et al. Full hematopoietic engraftment after allogeneic bone marrow transplantation without cytoreduction in a child with severe combined immunodeficiency. Blood 2001; 97: 809-811.